Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole M Verrills

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
The Clinical Biochemist. Reviews|November 2, 2006
Clinical proteomics: present and future prospectsNicole M Verrills
Blood|March 3, 2022
PP2A activation targets AML stem cellsNicole M Verrills
Current Opinion in Molecular Therapeutics|July 23, 2003
Drug resistance mechanisms in cancer cells: a proteomics perspectiveNicole M Verrills, Maria Kavallaris
Expert Opinion on Drug Discovery|March 14, 2017
Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancerHeather C Murray, Matthew D Dun, Nicole M Verrills
Cell Cycle (Georgetown, Tex.)|February 9, 2011
Controlling the cell cycle: the role of calcium/calmodulin-stimulated protein kinases I and IIKathryn A Skelding, John A P Rostas, Nicole M Verrills
Expert Review of Proteomics|November 22, 2024
Proteogenomic profiling of acute myeloid leukemia to identify therapeutic targetsHeather C Murray, Jonathan Sillar, Maddison Chambers, et al.
Pharmacology & Therapeutics|June 23, 2006
Mast cell function: regulation of degranulation by serine/threonine phosphatasesAlistair T R Sim, Russell I Ludowyke, Nicole M Verrills
Proteomics|February 9, 2024
Pharmaco-phosphoproteomic analysis of cancer-associated KIT mutations D816V and V560GHeather C Murray, Kasey Miller, Matthew D Dun, et al.
Respiratory Research|October 19, 2019
Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancerCassandra P Nader, Aylin Cidem, Nicole M Verrills, et al.
Pharmacology & Therapeutics|March 1, 2025
Understanding the regulatory landscape of protein phosphatase 2A (PP2A): Pharmacological modulators and potential therapeuticsDavid A Neale, Jonathan C Morris, Nicole M Verrills, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
The Clinical Biochemist. Reviews|November 2, 2006
Clinical proteomics: present and future prospectsNicole M Verrills
Blood|March 3, 2022
PP2A activation targets AML stem cellsNicole M Verrills
Current Opinion in Molecular Therapeutics|July 23, 2003
Drug resistance mechanisms in cancer cells: a proteomics perspectiveNicole M Verrills, Maria Kavallaris
Expert Opinion on Drug Discovery|March 14, 2017
Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancerHeather C Murray, Matthew D Dun, Nicole M Verrills
Cell Cycle (Georgetown, Tex.)|February 9, 2011
Controlling the cell cycle: the role of calcium/calmodulin-stimulated protein kinases I and IIKathryn A Skelding, John A P Rostas, Nicole M Verrills
Expert Review of Proteomics|November 22, 2024
Proteogenomic profiling of acute myeloid leukemia to identify therapeutic targetsHeather C Murray, Jonathan Sillar, Maddison Chambers, et al.
Pharmacology & Therapeutics|June 23, 2006
Mast cell function: regulation of degranulation by serine/threonine phosphatasesAlistair T R Sim, Russell I Ludowyke, Nicole M Verrills
Proteomics|February 9, 2024
Pharmaco-phosphoproteomic analysis of cancer-associated KIT mutations D816V and V560GHeather C Murray, Kasey Miller, Matthew D Dun, et al.
Respiratory Research|October 19, 2019
Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancerCassandra P Nader, Aylin Cidem, Nicole M Verrills, et al.
Pharmacology & Therapeutics|March 1, 2025
Understanding the regulatory landscape of protein phosphatase 2A (PP2A): Pharmacological modulators and potential therapeuticsDavid A Neale, Jonathan C Morris, Nicole M Verrills, et al.
Pageof 6